(PharmaNewsWire.Com, November 29, 2021 ) According to the new market research report, "Veterinary PoC Diagnostics Market by Product (Imaging Systems, Analyzers, Reagents), Technology (Immuno & Molecular Diagnostics), Application (Pathology, Bacteriology, Gynecology), Animal (Cat, Dog, Horse, Cattle), End User, Region-Global Forecast to 2025", size is projected to reach USD 2.4 billion by 2025 from USD 1.4 billion in 2019, at a CAGR of 8.9%.
Browse and in-depth TOC on "Veterinary PoC Diagnostics Market"
Growth in the companion animal population, rising demand for pet insurance, increasing number of veterinary practitioners in developed economies, and technological advancements are some of the factors driving the growth of this market during the forecast period.
In 2018, the consumables segment dominated the veterinary point-of-care diagnostics market
Based on the product, the consumables segment accounted for the largest share of the veterinary point-of-care diagnostics market in 2019. The increasing volume of clinical chemistry tests performed globally, due to the rising prevalence of chronic diseases in animals, has triggered the development of consumables.
By technology, the clinical biochemistry segment accounted for the largest share of the veterinary point-of-care diagnostic kits and analyzers market in 2018
Based on technology, the market is segmented into immunodiagnostics, clinical biochemistry, molecular diagnostics, hematology, urinalysis, and other technologies. In 2018, the clinical biochemistry segment accounted for the largest share of the veterinary point-of-care diagnostic kits and analyzers industry. The higher preference for various advanced clinical diagnostic products by veterinarians and pet owners are contributing to the large share of this segment.
By application, the clinical pathology segment accounted for the largest market share in 2018
Based on application, the veterinary point-of-care diagnostics market is segmented into clinical pathology, bacteriology, virology, parasitology, and other applications. The clinical pathology segment accounted for the largest market share in 2018. This segment is also projected to register the highest CAGR during the forecast period. The growth in this segment can be attributed to the increasing adoption of chemistry analyzers for the primary diagnosis of diseases in clinics.
By animal type, the companion animals segment accounted for the largest share of the veterinary point-of-care diagnostics market in 2018
Based on animal type, the market is segmented into companion and livestock animals. In 2018, the companion animals segment accounted for the largest share of the veterinary point-of-care diagnostics market. The increasing companion animal ownership, growing awareness about animal health among pet owners, and rising pet healthcare expenditure are some the factors stimulating the growth of this segment.
By end user, the veterinary clinics segment accounted for the largest share of the veterinary point-of-care diagnostics market in 2018
Based on end user, the market is segmented into veterinary hospitals & academic institutes, veterinary clinics, and home care settings. In 2018, the veterinary clinics segment accounted for the largest share of the market. The large share of this segment is attributed to the growing number of patients visiting vet clinics and the increasing number of private clinical practices.
Prominent players in the veterinary point-of-care diagnostics market include Zoetis, Inc. (US), IDEXX Laboratories, Inc. (US), Heska Corporation (US), Virbac (France), Thermo Fisher Scientific, Inc. (US), Eurolyser Diagnostica GmbH (Austria), Woodley Equipment Company (UK), Randox Laboratories LTD. (UK), AniPOC, Ltd. (UK), Carestream Health, Inc. (a part of ONEX Corporation) (Canada), NeuroLogica Corporation (a part of Samsung Electronics Co. Ltd.) (South Korea), and FUJIFILM SonoSite (a part of FUJIFILM Holdings Corporation) (Japan).
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, “Knowledgestore” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including: